Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACABNASDAQ:CGCNASDAQ:GOSSNASDAQ:RZLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACABAtlantic Coastal Acquisition Corp. II$5.77-47.1%$8.44$5.75▼$13.00$47.14M0.019,443 shs162,400 shsCGCCanopy Growth$1.41-5.4%$1.16$0.77▼$14.92$259.25M0.926.73 million shs19.05 million shsGOSSGossamer Bio$0.96-2.1%$1.10$0.50▼$1.55$217.75M1.881.58 million shs2.46 million shsRZLTRezolute$3.85-2.8%$3.36$2.22▼$6.19$233.06M0.97592,266 shs685,900 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACABAtlantic Coastal Acquisition Corp. II0.00%0.00%0.00%0.00%-46.43%CGCCanopy Growth0.00%+18.49%+34.29%-36.49%-84.28%GOSSGossamer Bio0.00%+14.08%-17.39%+3.04%+35.30%RZLTRezolute0.00%+40.00%+31.85%-19.96%+33.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACABAtlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/AN/AN/AN/ACGCCanopy Growth2.6447 of 5 stars2.54.00.00.02.30.01.3GOSSGossamer Bio3.9752 of 5 stars3.52.00.04.73.61.70.0RZLTRezolute2.5287 of 5 stars3.62.00.00.02.04.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACABAtlantic Coastal Acquisition Corp. II 0.00N/AN/AN/ACGCCanopy Growth 1.00Sell$2.0041.84% UpsideGOSSGossamer Bio 3.00Buy$7.50682.64% UpsideRZLTRezolute 3.14Buy$26.43586.46% UpsideCurrent Analyst Ratings BreakdownLatest ACAB, RZLT, GOSS, and CGC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025GOSSGossamer BioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.003/18/2025GOSSGossamer BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/14/2025GOSSGossamer BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$4.00 ➝ $4.002/13/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.002/13/2025RZLTRezoluteJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $9.002/10/2025RZLTRezoluteGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy2/5/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.002/4/2025RZLTRezoluteCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy1/30/2025GOSSGossamer BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACABAtlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/AN/ACGCCanopy Growth$276.75M0.94N/AN/A$2.72 per share0.52GOSSGossamer Bio$114.70M1.90N/AN/A$0.28 per share3.42RZLTRezoluteN/AN/AN/AN/A$1.65 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACABAtlantic Coastal Acquisition Corp. IIN/AN/A0.00∞N/AN/AN/AN/AN/ACGCCanopy Growth-$487.23M-$3.80N/AN/AN/A-156.98%-56.52%-24.18%5/29/2025 (Estimated)GOSSGossamer Bio-$179.82M-$0.26N/AN/AN/AN/A-127.28%-22.12%5/6/2025 (Estimated)RZLTRezolute-$68.46M-$1.22N/AN/AN/AN/A-70.27%-62.41%5/13/2025 (Estimated)Latest ACAB, RZLT, GOSS, and CGC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q3 2025RZLTRezolute-$0.22N/AN/AN/AN/AN/A5/6/2025Q1 2025GOSSGossamer Bio-$0.19N/AN/AN/A$3.95 millionN/A3/18/2025Q4 2024GOSSGossamer Bio-$0.15-$0.15N/A-$0.15$7.02 million$9.38 million2/12/2025Q2 2025RZLTRezolute-$0.33-$0.22+$0.11-$0.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACABAtlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/ACGCCanopy GrowthN/AN/AN/AN/AN/AGOSSGossamer BioN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACABAtlantic Coastal Acquisition Corp. IIN/AN/AN/ACGCCanopy Growth0.743.522.58GOSSGossamer Bio3.646.746.74RZLTRezoluteN/A9.309.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACABAtlantic Coastal Acquisition Corp. II23.30%CGCCanopy Growth3.33%GOSSGossamer Bio81.23%RZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipACABAtlantic Coastal Acquisition Corp. II91.19%CGCCanopy Growth1.30%GOSSGossamer Bio5.00%RZLTRezolute18.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACABAtlantic Coastal Acquisition Corp. II48.17 million720,000Not OptionableCGCCanopy Growth3,150183.87 million153.39 millionOptionableGOSSGossamer Bio180227.22 million215.27 millionOptionableRZLTRezolute4060.54 million49.40 millionOptionableACAB, RZLT, GOSS, and CGC HeadlinesRecent News About These CompaniesMarshall Wace LLP Sells 285,409 Shares of Rezolute, Inc. (NASDAQ:RZLT)April 27 at 4:33 AM | marketbeat.comRezolute, Inc. (NASDAQ:RZLT) Receives Consensus Rating of "Buy" from AnalystsApril 27 at 4:19 AM | marketbeat.comMaxim Group Sticks to Its Buy Rating for Rezolute (RZLT)April 26 at 10:38 PM | markets.businessinsider.comCraig-Hallum Sticks to Its Buy Rating for Rezolute (RZLT)April 26 at 9:16 AM | markets.businessinsider.comRezolute, Inc. Announces Closing of Underwritten Offering | RZLT Stock NewsApril 25 at 5:41 PM | gurufocus.comRezolute, Inc. Announces Closing of Underwritten OfferingApril 25 at 5:41 PM | gurufocus.comRezolute, Inc. Closes $96.9 Million Offering of Common Stock and Pre-Funded WarrantsApril 25 at 5:19 PM | quiverquant.comRezolute, Inc. Announces Closing of Underwritten OfferingApril 25 at 4:30 PM | globenewswire.comRezolute Stock Price, Quotes and ForecastsApril 24 at 8:23 PM | benzinga.comRezolute announces DMC recommendation to continue Phase 3 sunRIZE studyApril 23, 2025 | markets.businessinsider.comRezolute prices 20.79M shares at $3.25 in underwritten offeringApril 23, 2025 | markets.businessinsider.comBiotech Stock Surges After Encouraging Data Monitoring Committee RecommendationApril 23, 2025 | msn.comRezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In DecemberApril 23, 2025 | benzinga.comRezolute, Inc. Announces Pricing of Underwritten Offering for 20.8 Million Shares at $3.25 Per ShareApril 23, 2025 | quiverquant.comRezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded WarrantsApril 23, 2025 | globenewswire.comRezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)April 23, 2025 | globenewswire.comIs Rezolute (NASDAQ:RZLT) In A Good Position To Deliver On Growth Plans?April 22, 2025 | finance.yahoo.comWalleye Capital LLC Takes $2.41 Million Position in Rezolute, Inc. (NASDAQ:RZLT)April 21, 2025 | marketbeat.comAffinity Asset Advisors LLC Sells 125,000 Shares of Rezolute, Inc. (NASDAQ:RZLT)April 17, 2025 | marketbeat.comRezolute (RZLT) Upgraded to Buy: What Does It Mean for the Stock?April 11, 2025 | zacks.comRezolute, Inc. (NASDAQ:RZLT) Shares Sold by ADAR1 Capital Management LLCApril 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACAB, RZLT, GOSS, and CGC Company DescriptionsAtlantic Coastal Acquisition Corp. II NASDAQ:ACABAtlantic Coastal Acquisition Corp. II does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in financial services industry and mobility sector. The company was incorporated in 2021 and is based in New York, New York. Atlantic Coastal Acquisition Corp. II is a subsidiary of Atlantic Coastal Acquisition Management II LLC.Canopy Growth NASDAQ:CGC$1.41 -0.08 (-5.37%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.41 +0.00 (+0.28%) As of 04/25/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.Gossamer Bio NASDAQ:GOSS$0.96 -0.02 (-2.13%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.96 0.00 (-0.03%) As of 04/25/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Rezolute NASDAQ:RZLT$3.85 -0.11 (-2.78%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$3.88 +0.02 (+0.65%) As of 04/25/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
